{"title":"亲和力增强T细胞是HIV治疗的未来吗?","authors":"B. Jakobsen, A. Sewell, C. June","doi":"10.2217/17584310.3.2.105","DOIUrl":null,"url":null,"abstract":", suggesting that under rare circumstances HIV-1 infection can be effectively controlled by a protective T-cell response.T-cell exhaustion has been most thoroughly studied using the lymphocytic choriomenin-gitis virus (LCMV) model. Mice clear wild-type LCMV infection rapidly and protective memory develops. By contrast, a two amino-acid substitu-tion mutant of LCMV (Clone 13) is not cleared and a chronic, persistent infection ensues","PeriodicalId":88510,"journal":{"name":"HIV therapy","volume":"5 1","pages":"105-108"},"PeriodicalIF":0.0000,"publicationDate":"2009-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Are affinity-enhanced T cells the future of HIV therapy?\",\"authors\":\"B. Jakobsen, A. Sewell, C. June\",\"doi\":\"10.2217/17584310.3.2.105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\", suggesting that under rare circumstances HIV-1 infection can be effectively controlled by a protective T-cell response.T-cell exhaustion has been most thoroughly studied using the lymphocytic choriomenin-gitis virus (LCMV) model. Mice clear wild-type LCMV infection rapidly and protective memory develops. By contrast, a two amino-acid substitu-tion mutant of LCMV (Clone 13) is not cleared and a chronic, persistent infection ensues\",\"PeriodicalId\":88510,\"journal\":{\"name\":\"HIV therapy\",\"volume\":\"5 1\",\"pages\":\"105-108\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2009-03-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/17584310.3.2.105\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/17584310.3.2.105","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Are affinity-enhanced T cells the future of HIV therapy?
, suggesting that under rare circumstances HIV-1 infection can be effectively controlled by a protective T-cell response.T-cell exhaustion has been most thoroughly studied using the lymphocytic choriomenin-gitis virus (LCMV) model. Mice clear wild-type LCMV infection rapidly and protective memory develops. By contrast, a two amino-acid substitu-tion mutant of LCMV (Clone 13) is not cleared and a chronic, persistent infection ensues